Progestational drugs
Executive Summary
FDA is revoking its 1989 guidance requiring a boxed warning about an increased risk of birth defects associated with the use of progestational drugs during the first four months of pregnancy. FDA proposed a withdrawal of the guidance in April, and received no comments